PT-141 vs Viagra®, Kisspeptin, Melanotan II and Apomorphine

Key facts

• Viagra® is an FDA-approved tablet for ED that acts in the erectile tissue. Bremelanotide acts on melanocortin receptors.
• Vyleesi® and Addyi® are both FDA-approved for hypoactive sexual desire disorder (HSDD), for different groups of women. Neither is indicated in men.
• Compounded PT-141 is not FDA-approved.
• Kisspeptin is investigational, and the FDA lists kisspeptin-10 among bulk substances that may present significant safety risks.
• Melanotan II is not approved for any therapeutic use, and the FDA points to case reports of serious harm.
• A provider decides what fits your health history.

PT-141 vs Viagra®

Viagra® is a tablet containing sildenafil, FDA-approved for erectile dysfunction. Its label describes a PDE5 inhibitor that works in the erectile tissue when sexual stimulation releases nitric oxide. Bremelanotide acts on melanocortin receptors instead. No PT-141 product is FDA-approved for ED, and compounded PT-141 is not FDA-approved.

The sources on this page include no large trial comparing the two. One early study looked at PT-141 in men who had not done well on Viagra®, and one small study of 19 men gave low doses of nasal PT-141 with sildenafil. Viagra® is FDA-approved for ED, and no source on this page shows PT-141 works as well.

The Viagra® label says combining it with other ED treatments has not been studied and is not recommended. The Cialis® label also says combinations of tadalafil with other ED treatments have not been studied. CHROMA X Max combines tadalafil with PT-141 and oxytocin in one compounded tablet, no study on this page tested that mix, and the tablets are not used with other PDE5 medicines. If tablets have stopped working, this guide to your options goes further.

PT-141 vs kisspeptin

Kisspeptin is a natural hormone that activates the reproductive hormone system, and it is being studied for low desire. Two small trials in the UK gave kisspeptin-54 by intravenous infusion to people with HSDD in a research setting. The trial in women reported changes in how the brain processed sexual and attraction cues. The trial in men reported changes in brain activity and more penile tumescence in response to sexual videos, and its authors called this early promise.

A 2026 review in Sexual Medicine Reviews says kisspeptin remains investigational. The FDA lists kisspeptin-10 in category 2 of bulk substances for compounding, and says it has no, or only limited, safety information for the proposed routes. Vyleesi® has FDA approval and phase 3 trials in premenopausal women, and neither extends to compounded PT-141.

PT-141 vs melanotan II

The two are related. A published review describes PT-141 as a derivative and likely metabolite of melanotan II, and both act on melanocortin receptors without much selectivity. Their standing is very different. Vyleesi® has FDA approval in premenopausal women, and that does not extend to compounded PT-141. A 2024 review says melanotan II is not approved for any therapeutic use, can be bought online and is typically self-administered to darken the skin.

The FDA says compounded drugs containing melanotan II may pose a risk of immune reactions, and that published case reports discuss serious adverse events including melanoma and priapism. It lists melanotan II among substances once in category 2 whose nominations were withdrawn. A 2026 review of tanning products in the Journal of Clinical and Aesthetic Dermatology adds rhabdomyolysis and kidney infarction to the harms reported with unregulated melanotan I and II.

Case reports do not prove the cause, and the 2024 review notes that people who developed melanoma had other risk factors. It still advises people to avoid unlicensed agents including melanotan II.

PT-141 vs apomorphine

Apomorphine is a dopamine agonist. In the U.S., Apokyn® is an FDA-approved injection for off episodes in advanced Parkinson's disease, not for sexual problems. In Europe, an apomorphine product called Uprima® was authorised for erectile dysfunction in 2001. That authorisation ended in 2006, when the company did not renew it, for commercial reasons.

The Apokyn® label warns of nausea and vomiting, low blood pressure, fainting, heart rhythm changes and prolonged painful erections. It also says apomorphine must not be used with ondansetron or related anti-nausea medicines, after reports of severe low blood pressure and loss of consciousness. Those warnings come from that injection. No FDA label covers apomorphine in a compounded tablet, so a provider weighs them against your health history. CHROMA 4X, listed on the Sexual Health page, is a compounded tablet that holds apomorphine among its actives, and it is not FDA-approved.

Bremelanotide vs flibanserin

Vyleesi® (bremelanotide) and Addyi® (flibanserin) are both FDA-approved for acquired, generalized HSDD in women. Vyleesi® is an injection and Addyi® is a tablet.

They cover different groups. The Vyleesi® label covers premenopausal women and excludes postmenopausal women. The Addyi® label, revised in December 2025, covers women less than 65 years of age. Neither is indicated in men or to enhance sexual performance, and both labels say the way they work in HSDD is not known.

Their main cautions differ too. Addyi® carries a boxed warning for low blood pressure and fainting with alcohol taken close in time, with certain medicines that raise its levels, and with liver impairment. Vyleesi® warns of a temporary rise in blood pressure, patches of darker skin and nausea. Neither label compares the two. Compounded PT-141 is neither of these products, and it is not FDA-approved. This guide to prescription options sets out the wider picture for women.

How do you choose between them?

You do not have to choose alone. Some of these are not prescription options at all: kisspeptin is still investigational, and melanotan II is not approved for any therapeutic use. A provider looks at your health history, your medicines and what you have tried, then decides what fits.

Frequently asked questions

About CHROMA23®

CHROMA23® brings weight loss, longevity, sexual health, hair, and skincare into one place. Every prescription decision is made by an independent provider licensed in the patient's state, where available, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. One clear price per plan, shown in full before you pay. The medicine is real. The provider is real.

Sources

1. Viagra® (sildenafil) full prescribing information
2. Cialis® (tadalafil) full prescribing information
3. Vyleesi® (bremelanotide injection) full prescribing information, revised October 2026
4. Addyi® (flibanserin) full prescribing information (DailyMed)
5. Apokyn® (apomorphine) full prescribing information (DailyMed)
6. European Medicines Agency: Uprima® (apomorphine), authorisation withdrawn
7. Rosen et al.: subcutaneous PT-141 in healthy men and men with an inadequate response to Viagra® (International Journal of Impotence Research, 2004)
8. Diamond et al.: intranasal PT-141 given with sildenafil (Urology, 2005)
9. Mills et al.: kisspeptin in men with hypoactive sexual desire disorder (JAMA Network Open, 2023)
10. Thurston et al.: kisspeptin in women with hypoactive sexual desire disorder (JAMA Network Open, 2022)
11. King et al.: melanocortin receptors, melanotropic peptides and penile erection (Current Topics in Medicinal Chemistry, 2007)
12. Böhm et al.: benefits and risks of chronic melanocortin 1 receptor activation (Journal of the European Academy of Dermatology and Venereology, 2024)
13. Resnick et al.: insights into tanning biology and tanning products (Journal of Clinical and Aesthetic Dermatology, 2026)
14. FDA: certain bulk drug substances that may present significant safety risks
15. Vasylieva et al.: peptides in urology and sexual medicine, a narrative review (Sexual Medicine Reviews, 2026)
16. FDA: compounding and the FDA, questions and answers

Keep reading